Magnifica is proud to announce the signing of a major strategic partnership with Tony G Co-Investment Holdings Ltd., a Canada-based publicly listed company, aimed at producing NAD and NADH in Italy.
Magnifica, a leader in international business consulting with expertise in research and development of innovative solutions in the health and wellness sector, joins forces with Tony G Co-Investment Holdings Ltd., a company recognized for its investments and cutting-edge technologies.
This partnership marks a significant step forward in strengthening Italy’s scientific industry and, above all, in creating new “Made in Italy” products. The new venture, an innovative startup based in Rome, will focus on developing and producing in Italy—through the use of artificial intelligence—the molecules NAD (Nicotinamide Adenine Dinucleotide) and NADH, which are crucial to a wide range of biological processes fundamental to health and wellness.
The collaboration between Magnifica and Tony G Co-Investment Holdings Ltd. will bring advanced technologies and shared scientific expertise to ensure the production of high-quality NAD and NADH in Italy. This will help meet the growing demand for these molecules in both national and international markets, contributing to the promotion of global health and wellbeing.
Magnifica CEO, Tiziana Zampieri, commented:
“We are excited to collaborate with and support Tony G Co-Investment Holdings Ltd. in bringing NAD and NADH production to Italy. This partnership represents a unique opportunity to combine Italian scientific expertise—particularly in terms of high production quality standards—with financial resources to develop innovative solutions in the field of health and wellness.”